Due to a lack of consensus among all parties, Qingdao Haier Biomedical Co., Ltd. has pressed the termination button on the merger with Shanghai RAAS Blood Products | Read the announcement quickly.

① The reason for terminating the reorganization is that the main shareholders of the trading parties and the merging parties failed to formulate a specific plan recognized by all relevant parties; ② Shanghai RAAS Blood Products and Qingdao Haier Biomedical Co., Ltd. will resume trading on January 7 and announce a share buyback simultaneously; ③ According to informed sources, the goal of Haier Group to expand its health sector will not change.

cls.cnJan 6 10:59 ET

The seasonal influenza A has entered the epidemic period, and the sales of related Chinese Patent Medicine products have significantly increased.

① Recently, the positive rate of influenza virus has significantly increased, with over 99% being type A influenza. Market data shows a clear increase in the demand for various Traditional Chinese Medicine cold medicine products. ② Today, stock prices of several listed companies in the Traditional Chinese Medicine Industry, such as Shanxi Zhendong Pharmaceutical, Hainan Huluwa Pharmaceutical Group, and Zhongsheng Pharmaceutical, have reached the daily limit, with the Traditional Chinese Medicine Sector overall rising, and the Traditional Chinese Medicine 50 ETF increasing by 3.21%.

cls.cnJan 6 08:42 ET

Warner Pharmaceutical's centralized procurement plans to win bids for three products, and the proposed bid price for Silver Blade is at a high level compared to similar categories.

① Warner Pharmaceutical's Ginkgo Biloba Blade has been selected for the national Chinese Patent Medicine procurement alliance centralized purchasing (first batch expansion continuation), with the proposed winning price being high for the same category; ② In addition to the price, the final allocation of the procurement volume is also influenced by factors such as the recognition of Medical Institutions, the supply capability of enterprises, and the quality and safety of the products.

cls.cnJan 6 04:44 ET

The positive rate of influenza viruses nationwide continues to rise, and the sales of Against Influenza drugs continue to grow.

① According to the latest data from the China Center for Disease Control and Prevention, the positivity rate of influenza viruses continues to rise, with over 99% being type A influenza. ② As the number of influenza infections increases, the sales of antiviral drugs against influenza have also been growing recently. Currently, the antiviral flu medications available domestically mainly include Oseltamivir, Abidol, Mabalaosavir, Zanamivir, and Peramivir.

cls.cnJan 5 19:05 ET

Review of the A-share consecutive board leaders in 2024: Hainan Shuangcheng Pharmaceuticals and Guangdong Songfa Ceramics both achieved 14 consecutive boards, ranking first. Daqian Ecology & Environment Group and three other stocks followed closely with 1

① The 2024 A-share market has officially closed, with a number of stocks experiencing consecutive gains, among which Hainan Shuangcheng Pharmaceuticals and Guangdong Songfa Ceramics had the most days of consecutive price increases at 14; ② Attached is the ranking of the number of consecutive price increases of A-share listed companies in 2024 (attached table).

cls.cnDec 31 21:49 ET

Saudi ACWA's new milestone: Installed capacity of renewable energy projects in China has exceeded 1GW.

① The Saudi Wind Power giant ACWA announced that its renewable energy projects in China have a total installed capacity exceeding 1GW; ② These projects include wind power and photovoltaic projects, which are wholly or jointly owned by ACWA.

cls.cnDec 30, 2024 22:44 ET